Prelude Therapeutics IncorporatedPRLDNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P0
Near historical low
vs 3Y Ago
-1.3x
Contraction
Streak
4 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -17.12% |
| Q3 2025 | -15.81% |
| Q2 2025 | -10.52% |
| Q1 2025 | -8.87% |
| Q4 2024 | 7.34% |
| Q3 2024 | -0.18% |
| Q2 2024 | 7.66% |
| Q1 2024 | -9.64% |
| Q4 2023 | 15.50% |
| Q3 2023 | 5.19% |
| Q2 2023 | 14.34% |
| Q1 2023 | -15.60% |
| Q4 2022 | 13.02% |
| Q3 2022 | 7.41% |
| Q2 2022 | -6.62% |
| Q1 2022 | -9.36% |
| Q4 2021 | 10.81% |
| Q3 2021 | 1.39% |
| Q2 2021 | 36.06% |
| Q1 2021 | 13.02% |
| Q4 2020 | -4.71% |
| Q3 2020 | 56.43% |
| Q2 2020 | 14.53% |
| Q1 2020 | -3.54% |
| Q4 2019 | 61.18% |
| Q3 2019 | 10.46% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |